2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg

Dyslipidemias

Cardiovascular Risk Factor

Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.

L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg

Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.

Atorvastatin 10mg

World Health Organization: Global Status report on non-communicable diseases 2014.

Diagnostic and Treatments od the Dyslipidemias (Hypercholesterolemia) in adults. México, 2016.

Protocolo clínico para el diagnóstico y tratamiento de las Dislipidemias. CENAPRECE, Secretaría e Salud, D.F. México.

Treatment of lipids (including hypercholesterolemia) in secondary prevention.

Detección y Estratificación de Factores de Riesgo Cardiovascular. México, 2010.

Organization for Economic Cooperation and Development.

Laboratorios Grossman Sa

Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population

Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina

Evaluate the change of atorvastatin + l-carnitine vs. atorvastatin alone for dyslipidemia, through change of C-LDL in mg/dl

Evaluate the change of Cholesterol no-HDL in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.

Evaluate the change of serum levels of Cholesterol in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.

Evaluate the reduction of serum levels of Triglycerides in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment

Evaluate the change of serum levels of Cholesterol HDL in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment

Evaluate the incidence, of serious and non-serious adverse events related through the oral route administration of L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment in the subjects participating in the study

Laboratorios Grossman, S.A.

Instituto Nacional de Salud Publica, Mexico

Multiple Myeloma

Simvastatin

Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma.

Determination of the Efficacy and Feasibility of Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma - a Phase II Clinical Trial.

rhabdomyolysis/protease

Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population

Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma.

Täydellisin lääketieteellinen tietokanta tieteen tukemana